Composition
Each Minalip® tablet contains 20 mg of simvastatin
|
Indications
Minalip® is indicated for treatment of primary
hypercholesterolaemia or mixed dyslipidaemia.
- Minalip® is indicated for treatment of homozygous
familial hypercholesterolaemia.
|
Dosage
The dosage range is 5 - 40 mg/day given orally as a single dose in the evening. Adjustments of dosage, if required, should be made at intervals of not less than 4 weeks, to a maximum of 80 mg /day given as a single dose in the evening. The 80 mg dose is only recommended in patients with severe hypercholesterolaemia and at high risk for cardiovascular complications who have not achieved their treatment goals on lower doses and when the benefits are expected to outweigh the potential risks.
|
How Supplied
Box of 1 or 2 (AL/PVC) strips, each of 7 film coated
tablets and an inner leaflet.
|
Clinical Pharmacology
After oral ingestion, simvastatin, which is an inactive lactone, is hydrolyzed in the liver to the corresponding active beta-hydroxyacid form which has a potent HMG-CoA reductase (3 hydroxy – 3 methylglutaryl CoA reductase) inhibitory effect. This enzyme catalyses the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in the biosynthesis of cholesterol.
|